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The iatrogenic risk of HIV vertical transmission, calculated in initial epidemiologic studies, seemed to counterindicate invasive
prenatal diagnosis (PND) procedures. The implementation of highly active antiretroviral therapy (HAART) represented a turning
point in PNDmanagement, owing to a rapid and effective reduction of maternal viral load (VL). In the present study, we identified
cases of vertical transmission in HIV-infected pregnant women who did amniocentesis in the second trimester of pregnancy (𝑛 =
27), from 1996 to 2011. We divided our sample into Group A—women under HAART when submitted to amniocentesis (𝑛 = 20)
and Group B—women without antiretroviral therapy before amniocentesis (𝑛 = 7).We had 1 case of vertical transmission in Group
B. Preconceptional or early first trimester HIV serology is essential to avoid performing an amniocentesis without antiretroviral
therapy or viral suppression.When there is an indication for amniocentesis in an HIV-infected pregnant woman, it should be done
if the patient is on HAART and, if possible, when VL is undetectable. Nowadays, with combined first trimester screening test to
select pregnancies with high risk of aneuploidies, advanced maternal age is a less frequent indication to perform PND invasive
procedures, representing an outstanding gain in prenatal diagnosis of this population.
1. Introduction
The widespread use of highly active antiretroviral therapy
(HAART) during the last decade has significantly reduced
the rates of HIV mortality and disease progression [1].
The rate of vertical transmission in HIV-infected pregnant
women on HAART is around 1-2%, being almost zero when
associated with an elective cesarean delivery and avoidance
of breastfeeding [2]. Simultaneously, there has been an
increase in pregnancy rates among HIV-infected women,
raising new problems and issues in prenatal diagnosis (PND),
such as those concerning invasive procedures to diagnose
chromosomal abnormalities (amniocentesis and chorionic
villus sampling) [3].The increase in the mean maternal age is
a challenge in prenatal diagnosis, particularly inHIV-infected
pregnant women.
In the past, invasive procedures as amniocentesis were
generally discouraged in HIV-infected pregnant women, due
to increased risk of vertical transmission. The puncture of
the uterine wall or placenta and lesions of the fetal skin or
umbilical chord may all increase the fetal exposure to mater-
nal virus [4]. Amniocentesis itself has potential morbidity,
such as rupture ofmembranes, chorioamnionitis, or placental
abruption, with consequent fetal loss or vertical transmission
if gestation goes on [5].
Studies that analyze vertical transmission rates after
amniocentesis have been scant, and existing data are limited.
First studies report an increase in vertical transmission after
procedures undertaken during the second or third trimesters
of pregnancy [6–8]. However, during the pre-HAART era,
amniocentesis was not performed inmost of the centers, even
if there was a medical/obstetrical indication, and therefore
these studies include very small and heterogeneous samples.
Since 2003, the reported risk of vertical transmission has
markedly diminished [3, 9–11] because of the wide spread
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Figure 1: Summary of the study. HAART: highly active antiretroviral therapy; ARV: antiretroviral therapy.
of antiretroviral therapy. Some centers, thus, started to
offer amniocentesis during second trimester to HIV-infected
pregnant women, whenever a strong indication (genetic or
infectious) exists. These studies have reported no cases of
vertical transmission after invasive procedures among HIV-
infected women treated with HAART.
According to the British Guidelines [11], for women
who have started HAART but whose viral load is not yet
undetectable, it may be advisable to delay the amniocentesis
until the maternal viral load is undetectable if at all possible.
In women not already taking HAART, administration of
antiretroviral therapy to cover the procedure is advised.
The aim of our study was to identify cases of vertical
transmission in HIV-infected pregnant women who did
second trimester amniocentesis in our hospital.
2. Methods
We analysed amniocentesis (𝑛 = 27) performed in our insti-
tution from the observational cohort of HIV-infected preg-
nant women. The sample was obtained from the database,
which included all HIV-infected pregnant woman who gave
birth between 1996 and 2011 (𝑁 = 804). All clinical files were
reviewed and data were collected in order to obtain demo-
graphic characteristics of the sample, risk factors associated
with HIV infection (such as drug abuse), obstetrical variables
such as parity, mode of delivery, obstetrical complications,
indication of amniocentesis and gestational age when it
was accomplished, HIV subtype and transmission category,
antiretroviral regimen, viral load close to amniocentesis
and close to labour, fetal karyotype, newborn data such as
weight, antiretroviral prophylaxis regimen, and HIV DNA
PCR. Our sample was divided into two subgroups: women
under HAART when submitted to amniocentesis (Group A,
𝑛 = 20) and women without antiretroviral therapy before
amniocentesis (Group B, 𝑛 = 7) (Figure 1). SPSS Version 17.0
was used to obtain statistical analysis of both groups and to
compare differences in transmission rates among groups.The
results were analyzed statistically using Chi-square. A P value
below 0.05 was considered to indicate statistical significance.
Table 1: Demographic characteristics.
Demographics Group A(𝑁/%)
Group B
(𝑁/%)
Age (years)
Mean 37.7
<35 4/20% 1/14.3%
≥35 16/80% 6/85.7%
Race
Caucasian 15/75% 4/57.1%
African 4/20% 3/42.9%
Indian 1/5% —
Parity
Nulliparous 5/25% 2/28.6%
Category of transmission
Sexual 15/75% 7/100%
Substance abuse 4/20% —
Transfusional 1/5% —
Subtype of HIV
HIV 1 16/80% 5/71.4%
HIV 2 2/10% 2/28.6%
Double infection (HIV-1 and HIV-2) 2/10% —
This study was approved by the Ethical Committee of our
hospital.
3. Results
Between 1996 and 2011, amniocentesis was performed in
3.36% of our cohort (𝑁 = 804).
3.1. Demographics. The mean maternal age of our study
group was 37.7 years, and most of them were Caucasian and
multiparous (Table 1). Sexual transmission of HIV was the
main way of infection, and HIV 1 was the most frequent
subtype (𝑛 = 21). In Group A, 2 women had double infection
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Table 2: Characteristics of amniocentesis.
Characteristics of amniocentesis Group A(𝑁/%)
Group B
(𝑁/%)
Indication
Advanced maternal age 15/75% 5/71.4%
Increased NT 2/10% 1/14.3%
CMV Infection — 1/14.3%
Isoimmunization Rh 1/5% —
Maternal genetic disease (cystic fibrosis) 1/5% —
Malformation 1/5% —
GA (weeks)
13–15 — 1/14.3%
16–19 13/65% 4/57.1%
19–20 1/5% —
≥20 6/30% 2/28.6%
Chromosomal abnormalities
Trisomy 21 1/5% 1/14.3%
Viral load at the time of procedure (copies/mL)
(copies/
mL)
<50 11/55% —
50–999 5/25% —
1000–10000 1/5% —
>10000 3/15% —
Unknown — 7/100%
NT: nuchal translucency; GA: gestational age.
(HIV-1 and HIV-2) and other 2 were HIV-2 infected. The
remainingwomenwereHIV-1 infected. InGroup B, 2 women
had HIV-2 infection and 5 were HIV 1-infected.
3.2. Characteristics of Amniocentesis. Advancedmaternal age
was the most frequent indication for amniocentesis. Gesta-
tional age at the time of amniocentesis was, in most cases,
between 16 and 19weeks (Table 2). Two cases of chromosomal
abnormalities, both trisomy 21, were diagnosed. These two
amniocentesis were performed, one for advanced maternal
age and the other for augmented nuchal translucency.
In Group A, viral load (VL) at amniocentesis was unde-
tectable in 11 cases (2 of these patients were HIV-2 infected),
whereas in Group B viral load was unknown in all women.
However, in 2 women of Group B, who started prenatal
care only after amniocentesis, viral load was quantified
subsequently one HIV-2-infected woman had undetectable
viral load 4 weeks after the procedure and the other had 5.790
copies/mL 9 weeks after amniocentesis.
3.3. Pregnancy Outcome. Themost frequent obstetrical com-
plications in our study group were fetal growth restriction
(FGR), preterm labour, and chronic hypertension (Table 3).
Elective cesarean after 37 weeks was the predominant
mode of delivery in both groups. In Group A, VL determined
close to labor was undetectable in 13 women, and in Group
Table 3: Pregnancy outcome.
Pregnancy outcome Group A(𝑁/%)
Group B
(𝑁/%)
Obstetrical complications
Chronic hypertension 1/5% 1/14.3%
Foetal growth restriction 4/20% —
Gestational diabetes 1/10% 1/14.3%
Preterm labour/PPROM 4/20% —
Hydramnios 2/10% —
Infection (CMV) — 1/14.3%
Isoimmunization Rh 1/5%
Mode of delivery
Vaginal 4/20% 2/28.6%
Instrumental 1/5% —
Elective cesarian 14/70% 5/71.4%
Cesarian during labour 1/5% —
Viral load close to labour (copies/mL)
<50 13/65% 3/42.9%
50–999 5/25%
1000–10000 1/5%
>10000 1/5%
Unknown — 4/57.1%
PPROM: preterm premature rupture of membranes; GA: gestational age.
B it was undetectable in 4 women, the remaining 3 being
unknown.
Among the 27 newborns, only one case of HIV 1 infection
was diagnosed, owing to Group B. It occurred in a patient
with a diagnosis of HIV infection at 30 weeks of gestation
(in 1998), who had already done amniocentesis at 16 weeks
for primary CMVmaternal infection. Primary care physician
sent this patient at 9 weeks of gestation to our emergency
department due to a rash, which was interpreted as an
exanthem subitum. She was referred to our PND center
and laboratory tests of CMV, Toxoplasmosis, Rubella, and
Parvovirus B19 were requested. Since the patient had been
referred from primary care, HIV serology had already been
requested, and according to the patient, with pending results.
Therefore, it was not requested in our tertiary care center.
CMV results were positive for primary infection and the
amniocentesis was planned. However, this patient was absent
from medical care until 30 weeks, when she returned with
a diagnosis of HIV infection (requested by her primary care
physician), presumably due to a disease denial. Spontaneous
labour began at 38 weeks and she had a vaginal delivery. She
had done neither combination antiretroviral drug therapy
nor AZT prophylaxis during pregnancy, as well as adequate
prenatal care. AZT intravenous perfusion was done during
labour.
Among the 777 women who were not submitted to inva-
sive procedures, there were 4 cases of vertical transmission
(0.5%). When we compared this transmission rate with the
transmission rate of 1/27–3.7% (all HIV pregnant women
4 Infectious Diseases in Obstetrics and Gynecology
0 5 10 15 20
Group A
Group B
AZT
2 NRTI (AZT + 3TC)
2 NRTI + PI
2 NRTI + NNRTI
Figure 2: Antiretroviral therapy during pregnancy. AZT: zidovu-
dine; 3TC: lamivudine; NRTI: nucleoside reverse transcriptase
inhibitors; NNRTI: nonnucleoside reverse transcriptase inhibitors;
PI: protease inhibitors.
who underwent amniocentesis), no statistical significant
difference was found (4/777 versus 1/27; 𝑃 value = 0.4083; 𝜒2-
test). Comparing the difference in transmission rate between
Groups A and B, we obtained a 𝑃 value of 0.5756 (0/20 versus
1/7; 𝜒2-test).
3.4. Antiretroviral Therapy. Antiretroviral drug therapy in
pregnancy is described in Figure 2. In Group B, therapy
regimen was initiated in the second half of pregnancy,
because of late HIV diagnosis (only after amniocentesis).
Monotherapy prophylaxis with AZT was administrated to
three pregnant women in Group B.
4. Discussion
The absence of a control group and the small sample dimen-
sion raise some limitations to the statistical analysis in the
present work. This is also the case in studies performed by
other authors [3, 9–11].
In the particular case of vertical transmission in Group B,
we cannot exclude the possibility of a primary HIV infection
considering the rash as the initialmanifestation of the disease.
Primary HIV infection is a major risk factor for vertical
transmission. Concomitantly, primary infection for CMV
may reveal immunosuppression status of the patient, also
contributing to vertical transmission.
It is important to note that the long time span of our study
includes a period when AZT monotherapy was considered
to be the gold standard prophylaxis. Nowadays, regimens
of HAART are recommended during pregnancy with two
nucleoside reverse transcriptase inhibitors (NRTIs) and one
protease inhibitor (PI) [10], allowing to achieve a higher
efficacy and sustainability of viral suppression. According
to Watts’ review, the patient should have an optimized
antiretroviral treatment and an undetectable viral load before
undergoing an invasive procedure as amniocentesis [12]. In
addition, Lo´pez and Coll recommended that transplacental
amniocentesis should always be avoided [13]. Therefore, it
is important to propose a viral load determination before
amniocentesis for patients with contamination risk and to
postpone the invasive procedure in cases with positive results
in order to obtain an undetectable viral load [14].
In addition, considering that this study involves a long
time spam, it is also important to note that physicians have
not always been sensitized to ask for an HIV test before per-
forming PND invasive procedures. Also, advanced maternal
age was the predominant indication for amniocentesis in our
cohort. Nowadays, with combined first trimester screening
test to select pregnancies with high risk of aneuploidies,
advancedmaternal age is a less frequent indication to perform
PND invasive procedures. Among HIV-infected women this
important screening test minimizes invasive procedures,
representing an outstanding gain in prenatal diagnosis of this
population.
Somigliana et al., in a multicenter study, showed no
difference in transmission rate between mothers who under-
went an invasive procedure and the control group (2/60
versus 12/712) [15]. In our study, we obtained an overall
transmission rate of 4/777 (0.5%) in HIV pregnant women
without invasive procedures, and a transmission rate of 1/27
(3.7%) in those who had an amniocentesis (4/777 versus
1/27; 𝑃 value = 0.4083; 𝜒2-test). Therefore, due to the small
sample dimension of our study and to the inadequate power
for differences in transmission rates, there is no evidence
that amniocentesis is associated with a higher transmission
rate. This is also the case in other published series [8, 9, 11].
Moreover, when we compared transmission rates between
our two Groups A and B, we found no statistical significant
differences (0/20–0% versus 1/7–14.3%; 𝑃 value = 0.5756; 𝜒2-
test).
In our opinion, invasive PND techniques should not
be precluded to HIV-infected pregnant women at increased
risk for fetal chromosomopathies. However, it is extremely
important to adopt a selective attitude in these situations,
informing and clarifying the patient about the risks related
to the procedure. Besides the issue of perinatal transmission,
it is essential to remember the complications inherent to inva-
sive procedures, such as premature rupture of membranes,
chorioamnionitis, and placental abruption, as previously
stated.
5. Conclusions
Preconceptional or early first trimester HIV screening is
essential to avoid amniocentesis without antiretroviral ther-
apy or viral suppression. When amniocentesis is indicated in
HIV-infected pregnant women, it should be done after ini-
tiating a combination antiretroviral drug therapy and ideally
when viral load is undetectable.Thewide spread of combined
prenatal screening tests has been particularly important in
these patients, decreasing the need to perform invasive PND
procedures. Although the size of our sample is limited, there
was no case of vertical transmission among pregnant women
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with prenatal care, who have done amniocentesis onHAART.
It would be extremely important to analyze wider results, in
a multicentric study.
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